{"disease":{"id":"metastatic-her2-positive-gastroesophageal-junction-cancer","name":"metastatic her2 positive gastroesophageal junction cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT06650332","title":"Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT04727151","title":"TAC T-cells for the Treatment of HER2-positive Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":28,"lead_sponsor_name":"Triumvira Immunologics, Inc.","has_results":true},{"nct_id":"NCT04467515","title":"A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Precirix","has_results":true},{"nct_id":"NCT05207722","title":"CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Celularity Incorporated","has_results":false}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}